USP18 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL31238035	1.00	2/20
SCHEMBL9619484	0.67	2/20
SCHEMBL9619486	0.67	2/20
SCHEMBL14797847	0.67	2/20
SCHEMBL14797848	0.67	2/20
SCHEMBL22822868	0.66	2/20
SCHEMBL14880552	0.58	2/20
SCHEMBL15940048	0.58	2/20
SCHEMBL18802990	0.58	2/20
SCHEMBL22823111	0.57	2/20
SCHEMBL809473	0.56	2/20
SCHEMBL812720	0.56	2/20
SCHEMBL3437940	0.56	2/20
SCHEMBL3437943	0.56	2/20
SCHEMBL29169528	0.56	2/20
SCHEMBL22529623	0.56	2/20
SCHEMBL22529624	0.56	2/20
SCHEMBL22822873	0.56	2/20
SCHEMBL14798452	0.56	2/20
SCHEMBL14798453	0.56	2/20

Clinical trials — most relevant to USP18 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
18F-CP18 Imaging Studies for Cancer Treatment With Birinapant	PHASE2	WITHDRAWN
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer	PHASE2	COMPLETED
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection	PHASE2	WITHDRAWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Testing the Safety of CB-5339 in Patients With Cancer	PHASE1	WITHDRAWN
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease	EARLY_PHASE1	RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma	nan	COMPLETED
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Establishment of a Prospective Clinical-biological Database	nan	RECRUITING
Apoptosis Markers in Aggressive Periodontitis	nan	COMPLETED
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases	nan	UNKNOWN
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a USP18 binder may also engage these)

Protein	Name	Similarity
Q5RE63	—	1.000	Q5RE63 →
Q9WTV6	—	1.000	Q9WTV6 →
Q6P8X6	—	0.982	Q6P8X6 →
Q4R6D3	—	0.982	Q4R6D3 →
A2BGT0	—	0.976	A2BGT0 →
Q8R5K2	—	0.975	Q8R5K2 →
Q86UV5	—	0.974	Q86UV5 →
Q9FPS0	—	0.974	Q9FPS0 →
A5PMR2	—	0.974	A5PMR2 →
B1AY15	—	0.974	B1AY15 →
Q70EL3	—	0.972	Q70EL3 →
D6RJB6	—	0.972	D6RJB6 →
D6R9N7	—	0.972	D6R9N7 →
A6QNM7	—	0.971	A6QNM7 →
Q5ZM45	—	0.971	Q5ZM45 →
D6R901	—	0.971	D6R901 →
Q76LT8	—	0.970	Q76LT8 →
C9JVI0	—	0.970	C9JVI0 →
Q3V0C5	—	0.970	Q3V0C5 →
P0C7I0	—	0.970	P0C7I0 →
E9Q9U0	—	0.970	E9Q9U0 →
A8MUK1	—	0.970	A8MUK1 →
D6RBQ6	—	0.969	D6RBQ6 →
Q8BWR4	—	0.968	Q8BWR4 →
A0A0R4IB93	—	0.968	A0A0R4IB93 →
A6NCW7	—	0.968	A6NCW7 →
Q8TEY7	—	0.968	Q8TEY7 →
USP20	Ubiquitin carboxyl-terminal hydrolase 20	0.968	landscape →
Q8C2S0	—	0.968	Q8C2S0 →
Q8NB14	—	0.968	Q8NB14 →